This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Wall Street Analysts Believe Rapt Therapeutics (RAPT) Could Rally 122.22%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 122.2% in Rapt Therapeutics (RAPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Rapt Therapeutics (RAPT) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Rapt Therapeutics (RAPT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Best Momentum Stocks to Buy for July 15th
by Zacks Equity Research
FUTU, IVZ and RAPT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 15, 2025.
Does Rapt Therapeutics (RAPT) Have the Potential to Rally 183.83% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at an 183.8% upside potential for Rapt Therapeutics (RAPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
New Strong Buy Stocks for July 15th
by Zacks Equity Research
FUTU, PAAS, RAPT, HG and IVZ have been added to the Zacks Rank #1 (Strong Buy) List on July 15, 2025.
Wall Street Analysts Predict a 282.65% Upside in Rapt Therapeutics (RAPT): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 282.7% upside potential for Rapt Therapeutics (RAPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Rapt Therapeutics (RAPT) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Rapt Therapeutics (RAPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
All You Need to Know About Rapt Therapeutics (RAPT) Rating Upgrade to Buy
by Zacks Equity Research
Rapt Therapeutics (RAPT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Dr. Reddy's (RDY) Q1 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Dr. Reddy's (RDY) reports mixed first-quarter fiscal 2025 results, wherein earnings lag estimates, but revenues beat the same, driven by growth in global generics sales in North America and India.
Viking (VKTX) Q2 Earnings Beat, Stock Up on Pipeline Updates
by Zacks Equity Research
Viking (VKTX) gains 24% on better-than-expected second-quarter 2024 results, along with encouraging updates regarding its pipeline development plans.
Alkermes' (ALKS) Q2 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Alkermes (ALKS) reports mixed second-quarter 2024 results. Earnings and revenues decline year over year.
GSK Blenrep Combos for Multiple Myeloma Accepted for EU Review
by Zacks Equity Research
GSK announces the acceptance of its regulatory filing, seeking the approval of Blenrep combinations for the treatment of relapsed or refractory multiple myeloma, for review in the EU.
Agenus (AGEN) Tanks on Colorectal Cancer Study Interim Data
by Zacks Equity Research
The FDA rejects the accelerated approval pathway for Agenus' (AGEN) BOT/BAL combination in relapsed/refractory microsatellite stable colorectal cancer patients.
TEVA's Ajovy Meets Goal in Migraine Prevention Study for Kids
by Zacks Equity Research
TEVA achieves the primary efficacy endpoint with statistical significance in the phase III study of its marketed drug, Ajovy, for the prevention of episodic migraine in pediatric patients.
Bayer (BAYRY) Meets Primary Goal in Nubeqa Expanded-Use Study
by Zacks Equity Research
Bayer (BAYRY) meets the primary goal in the phase III study evaluating the darolutamide/ADT combo without docetaxel in metastatic hormone-sensitive prostate cancer patients.
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans
by Zacks Equity Research
Ultragenyx (RARE) reaches alignment with the FDA regarding the pivotal phase III study design and endpoints for GTX-102 for Angelman syndrome, which is scheduled to be initiated later this year.
Arcutis (ARQT) Stock Rises 31% in the Past Month: Here's Why
by Zacks Equity Research
Arcutis (ARQT) rises 30.9% in a month after the label expansion of its marketed product, Zoryve cream 0.15%, for the AD indication in adult and pediatric patients aged six years and older.
Lisata (LSTA) Stock Rallies More Than 30% YTD: Here's Why
by Zacks Equity Research
Lisata (LSTA) is progressing well with developing its lead investigational pipeline candidate, certepetide, which is being studied for various cancer indications.
Beam Therapeutics' (BEAM) CFO to Step Down, Stock Declines
by Zacks Equity Research
Beam Therapeutics' (BEAM) current chief financial officer, Terry-Ann Burrell, is set to step down from her role on Aug 9. The stock falls 4.7%.
Verastem (VSTM) Begins Dosing in Solid Tumors Study in China
by Zacks Equity Research
Verastem (VSTM) doses the first patient in a phase I/II study conducted by GenFleet Therapeutics, evaluating KRAS G12D inhibitor, GFH375/VS-7375 in solid tumors. Shares rise.
AbbVie (ABBV) Files for Rinvoq in Giant Cell Arteritis in US & EU
by Zacks Equity Research
AbbVie (ABBV) files regulatory applications to the FDA and the EMA, seeking approval for a new indication of Rinvoq, giant cell arteritis.
SpringWorks (SWTX) Rises More Than 40% in a Year: Here's Why
by Zacks Equity Research
SpringWorks' (SWTX) Ogsiveo is the first drug approved by the FDA to treat desmoid tumors. The company's efforts to develop its pipeline candidate, mirdametinib, for treating NF1-PN also hold promise.
Here's Why You Should Invest in Beam Therapeutics (BEAM) Now
by Zacks Equity Research
Here, we discuss why investing in Beam Therapeutics (BEAM) stock now may be a prudent move.
Athira (ATHA) Completes Dosing in Alzheimer's Study, Stock Up
by Zacks Equity Research
Athira (ATHA) completes dosing the last patient in the phase II/III LIFT-AD study on fosgonimeton for treating people with mild-to-moderate Alzheimer's disease. Stock gains.
Mirum (MIRM) Gets EC Approval for Livmarli Label Expansion
by Zacks Equity Research
The European Commission approves Mirum's (MIRM) Livmarli for the treatment of progressive familial intrahepatic cholestasis in patients three months of age and older.